Baird Maintains Outperform on Instil Bio, Raises Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen maintains an Outperform rating on Instil Bio (NASDAQ:TIL) and raises the price target significantly from $32 to $180.
September 13, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Jack Allen has maintained an Outperform rating on Instil Bio and significantly increased the price target from $32 to $180, indicating strong confidence in the company's future performance.
The significant increase in the price target from $32 to $180 by a reputable analyst suggests a strong positive outlook for Instil Bio. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100